Another prospective treatment for FSHD regarding DNA level was introduced by Rashnonejad et al. (2019), who developed a new Cas13/CRISPR mediated DUX4 mRNA silencing method which does not cleave DNA. The gene discussed is DUX4; the disease is facioscapulohumeral muscular dystrophy.